Trials / Active Not Recruiting
Active Not RecruitingNCT06533553
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Areteia Therapeutics · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexpramipexole Dihydrochloride | Administration of dexpramipexole tablet |
Timeline
- Start date
- 2024-07-09
- Primary completion
- 2025-10-01
- Completion
- 2025-12-01
- First posted
- 2024-08-01
- Last updated
- 2025-05-14
Locations
23 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06533553. Inclusion in this directory is not an endorsement.